Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.

While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...

Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...